From developing new molecules, through to collaborative research and joint working practices, innovation is key to the future of the UK’s healthcare economy and patient wellbeing.
Join ABPI CEO Stephen Whitehead as he discusses the price, value and our need to embrace innovation, NHS Confederation CEO Mike Farrar as he focuses on the meaning of innovation, and hear from representatives of the pharmaceutical industry, researchers and academics from across the healthcare sector. The conference will examine the UK as a centre for innovation, and look at how pioneering innovation has delivered patient benefits and has made strong economic contributions to the UK.
Stephen Whitehead, CEO of the ABPI, said:
“Our November conference provides us with an opportunity to highlight the importance of innovation. Innovation is fundamental for the on-going success of our industry, it is critical to the future well being of our healthcare economy, and to fulfilling future unmet clinical need.
“From researching and developing innovative new medicines, through to working with physicians and patients, through a collaborative approach we can bring real change to effective medical management, and most importantly we can improve patient healthcare.
“Innovation unites us. By working closely with all our stakeholders, patient groups and the NHS we can reinforce the vital role the UK plays as a global destination of choice for life sciences investment.”
Venue: Royal Society, 6 to 9 Carlton Terrace, London SW1Y 5AG.
To book your place at the event, please complete our online booking form at www.abpiannualevent.com.
ABPI Press Office
Tel: +44 (0) 20 7747 1410 or +44 (0) 20 7747 1441
Mobile: +44 (0) 7808 641810 or +44 (0) 7850 312064
About the ABPI
We represent innovative research-based biopharmaceutical companies, both large and small, leading an exciting new era of biosciences in the UK.
Our industry, a major contributor to the economy of the UK, brings life-saving and life-enhancing medicines to patients. Our members supply 90 per cent of all medicines used by the NHS, and are researching and developing 90 per cent of the current medicines pipeline, ensuring that the UK remains at the forefront of helping patients prevent and overcome diseases.
We are the Government recognised body negotiating the pricing of branded medicines on behalf of the entire industry. Working with our Research Affiliate Members, we promote the UK as a destination of choice for international life sciences investment.